Gilead's Viread: Smoothing the Path to Success

Gilead's successful European rollout of Viread was helped by the homogeneity and high concentration of the European HIV treatment market. Viread has in turn catalyzed the integration of Gilead's hitherto fragmented European operations. The US biotech can now exploit its strong European network to secure in-licensing candidates and maximize profits from in-house follow-ons.